John H. Johnson

Mr. Johnson is a recognized leader in the healthcare industry and has served as a member of our Board of Directors since July 2021. Mr. Johnson served as the Chief Executive Officer of Strongbridge Biopharma plc., a company focused on building a portfolio of vertical, therapeutically-aligned rare disease franchises, from July 2020 through October 2021, when it was sold to Xeris Biopharma Holdings, Inc. He also served as Strongbridge Biopharma’s Chairman from March 2015 to November 2019. Mr. Johnson previously served as the Chief Executive Officer of Melinta Therapeutics, a commercial stage company developing and commercializing novel antibiotics, from 2018 through 2020. He served as Chairman and Chief Executive Officer of Dendreon Corporation from 2012 through 2014. Mr. Johnson previously held various senior positions with Eli Lilly & Company, ImClone Systems, Inc., Johnson & Johnson, and Centocor Ortho Biotech. Mr. Johnson is currently on the Board of Directors of Xeris (NASDAQ:XERS), and (NASDAQ:VSTM). Mr. Johnson served as the non-executive chairman of the Board of Directors for Autolus Therapeutics plc. from September 2021 until April 2024 and executive chairman of Applied Therapeutics from December 2024 until November 2025. Mr. Johnson received his B.S. from University of Pennsylvania East Stroudsburg. Mr. Johnson’s qualifications to serve on our Board of Directors include his considerable leadership experience and specific knowledge of the healthcare industry.